MedTrace Logo

Pilot-Tart Cherry, Mitral Transcriptome, and POAF Incidence

NCT03793465 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2026-02-05

No results posted yet for this study

Summary

Assess impact of Tart Cherry Concentrate in cardiac surgical patients on POAF and related clinical and economic outcomes. Measure inflammation gene transcripts in cardiac tissue.

Conditions

  • Post-operative Atrial Fibrillation (POAF)

Interventions

DIETARY_SUPPLEMENT

tart cherry concentrate

Consume 2 servings (1 ounce or 2 tablespoon/serving) per day for three days before cardiac surgery

Sponsors & Collaborators

Principal Investigators

  • Steven F Bolling, MD · University of Michigan

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-08
Primary Completion
2027-01-31
Completion
2027-01-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03793465 on ClinicalTrials.gov